Nearly 300 treatable genetic disorders can be identified before birth, Harvard experts say.

The breakthrough could radically change the approach to prenatal medicine, allowing intervention in serious illnesses before symptoms appear or affect patients' quality of life.

A research team comprised of geneticists from Massachusetts General Hospital, Harvard Medical School, and Duke University has identified nearly 300 genetic disorders that can be treated during pregnancy or in the first week of life.

 This new "list of treatable fetal findings" represents a breakthrough with the potential to transform prenatal care, expand available therapeutic options, and enable interventions that could alter the natural course of serious diseases.

 The results of the study, published in the American Journal of Human Genetics, consolidate years of work in medical genetics and offer a concrete tool to improve the prognosis of hundreds of conditions that, until recently, eluded any possibility of early treatment.

                                                                               

“We saw a critical gap in prenatal care and an opportunity to define genetic disorders that are treatable during this period,” said Dr. Nina Gold, director of Prenatal Medical Genetics at Massachusetts General Hospital and assistant professor of pediatrics at Harvard.

 The specialist also noted that “these conditions are actionable, meaning that with diagnostic information, we can intervene early and improve outcomes.”

Genomic sequencing technology, which has evolved rapidly in the last decade, is emerging as a key tool in this process. Combined with family history, this technique can identify genes responsible for abnormalities detected by ultrasound and also reveal incidental findings that could predispose the fetus to developing serious, yet treatable, diseases.

Simply put, if doctors know about a congenital heart disease or metabolic disorder before birth, they can act quickly as soon as the baby is born, and in some cases even intervene during pregnancy.

“The use of genomic sequencing (GS) for the prenatal diagnosis of fetuses with sonographic abnormalities has grown enormously in the last decade. Fetal GS also offers the opportunity to identify incidental genomic variants that are unrelated to the fetal phenotype but may be relevant to fetal and neonatal health,” the experts stated in the scientific study.

The researchers also clarified that there are currently no guidelines for reporting incidental fetal GS findings.

“In the United States, GS for adults and children is recommended to include a list of ‘secondary findings’ genes that are associated with disorders for which surveillance or treatment can reduce morbidity and mortality. These cause adult-onset disorders. Importantly, many fetal- and childhood-onset genetic disorders are also treatable. One proposed solution is to create a list of treatable fetal findings, which can be offered to pregnant individuals undergoing fetal GS or, eventually, as a standalone cell-free DNA screening test,” they stated.

A list with clinical and ethical implications

Constructing this list wasn't just a theoretical exercise. The researchers conducted an extensive review of the medical literature to identify 296 genetic conditions with evidence of positive response to early treatments. Some of these conditions are on the fringes of fetal medicine, with emerging therapies still in clinical development. Others already have standardized postnatal interventions that, when applied early, can prevent irreversible damage.

"One of our goals is to expand a family's options during pregnancy," said Jennifer Cohen, a medical geneticist at Duke University Hospital and lead author of the study. "These gene lists are intended to offer the possibility of early intervention, which in some cases can change the natural history of the disease," a statement that clearly summarizes the spirit of the work: not just to detect, but to offer alternatives.

 For example, some of the disorders included in the list can be addressed with neonatal medication or specific support therapies, such as controlled fluid and electrolyte administration in cases of gastrointestinal disorders. Others involve corrective surgeries or intensive follow-up protocols that significantly improve the newborn's quality of life. In more exceptional situations, fetal medicine even allows for intrauterine treatments, which are now explored in specialized centers.

However, this diagnostic revolution does not come without caveats. The possibility of having detailed genetic information before birth also raises ethical dilemmas and challenges in the clinical setting.

 The researchers emphasize the need for interdisciplinary teams that include medical geneticists, obstetricians, neonatologists, and bioethicists. Only then, they assert, will it be possible to adequately manage the volume of information and the clinical decisions it can trigger.

 In Dr. Gold's words: "Our goal in creating this specific list of treatable fetal findings is to improve medical care, but we are aware of the challenges that physicians, genetic counselors, and patients face when dealing with new health information during pregnancy or immediately after birth. That is why it is so important to work as a team to empower our patients and provide them with the clearest information possible."

                                                                           

A starting point for the future

The publication of this list opens a path that is just beginning to be explored. Its implementation could be extended to genetic screening programs during pregnancy, offering families the possibility of accessing more accurate diagnoses and taking action earlier. However, its value lies not only in detection but in its immediate clinical applicability.

The conditions included in the list meet an essential criterion: they can be treated. This is not abstract information or findings with merely predictive value, but rather data that can save lives, prevent disabilities, and improve the prognosis of complex diseases.

This approach also opens up new perspectives for fetal medicine, a field that has evolved rapidly thanks to advances in imaging, intrauterine surgery, and targeted therapies. The possibility of understanding a fetus's genetic makeup and taking action before birth represents one of the most powerful promises of personalized medicine. Although technological hurdles and ethical debates remain to be resolved, the trend seems clear: genetics will be a fundamental pillar of prenatal care in the future.

 Researchers acknowledge that not all of the conditions included in the list currently have fully developed therapies. Some are at the forefront of clinical research and require further study. Others, however, have well-established approaches, such as certain metabolic diseases that, if diagnosed early, can be treated with specific diets from birth. The advantage of grouping these disorders under a single "treatability" criterion is that it facilitates their incorporation into clinical protocols and improves counseling for parents.

These types of advances also highlight the role of genetic education in the training of physicians and healthcare professionals. As this specialty becomes integrated into daily clinical practice, it becomes essential to have professionals trained to interpret genomic sequences, assess risks, and emotionally support families in highly sensitive contexts.

 In short, what until recently seemed unattainable is now emerging as an emerging standard. The combination of genetic technology, fetal medicine, and comprehensive patient care has made a paradigm shift possible. That's why intervening before birth, when there's still time to change the course of a disease, not only improves the prognosis but also redefines what it means to care for one's health from the first moment of life.